Aprea Therapeutics Inc. (NASDAQ:APRE) went up by 11.37% from its latest closing price compared to the recent 1-year high of $31.45. The company’s stock price has collected -4.34% of loss in the last five trading sessions. Press Release reported 1 hour ago that Thinking about buying stock in Chembio Diagnostics, Endo, Aprea Therapeutics, RealReal, or Amplify Energy?
Is It Worth Investing in Aprea Therapeutics Inc. (NASDAQ :APRE) Right Now?
Opinions of the stock are interesting as 1 analysts out of 5 who provided ratings for Aprea Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.00, which is $1.6 above the current price. APRE currently public float of 19.04M and currently shorts hold a 9.93% ratio of that float. Today, the average trading volume of APRE was 3.01M shares.
APRE’s Market Performance
APRE stocks went down by -4.34% for the week, with a monthly jump of 5.19% and a quarterly performance of 15.23%, while its annual performance rate touched -82.15%. The volatility ratio for the week stands at 5.32% while the volatility levels for the past 30 days are set at 6.72% for Aprea Therapeutics Inc.. The simple moving average for the period of the last 20 days is 10.35% for APRE stocks with a simple moving average of -48.92% for the last 200 days.
Analysts’ Opinion of APRE
Berenberg, on the other hand, stated in their research note that they expect to see APRE reach a price target of $37. The rating they have provided for APRE stocks is “Buy” according to the report published on December 16th, 2020.
JP Morgan gave a rating of “Neutral” to APRE, setting the target price at $25 in the report published on September 29th of the previous year.
APRE Trading at 18.41% from the 50-Day Moving Average
After a stumble in the market that brought APRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.05% of loss for the given period.
Volatility was left at 6.72%, however, over the last 30 days, the volatility rate increased by 5.32%, as shares surge +22.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.31% upper at present.
During the last 5 trading sessions, APRE rose by +11.44%, which changed the moving average for the period of 200-days by -77.28% in comparison to the 20-day moving average, which settled at $5.17. In addition, Aprea Therapeutics Inc. saw 3.05% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at APRE starting from Redmile Group, LLC, who sale 500,000 shares at the price of $5.58 back on Dec 28. After this action, Redmile Group, LLC now owns 1,768,718 shares of Aprea Therapeutics Inc., valued at $2,791,290 using the latest closing price.
5AM Ventures IV, L.P., the Former 10% holder of Aprea Therapeutics Inc., sale 175,000 shares at $25.30 during a trade that took place back on Oct 05, which means that 5AM Ventures IV, L.P. is holding 138,497 shares at $4,427,500 based on the most recent closing price.
Stock Fundamentals for APRE
Equity return is now at value -64.00, with -55.00 for asset returns.